Chapter 9 #2
The talk is fifty minutes. I use my right hand for the slides and my voice for the data and my brain for the story, and the story is this: that the traditional model of clinical trial design assumes you know the right dose before you start testing it, and that assumption is wrong, and that wrongness has cost patient lives, and that my framework — sequential Bayesian adaptation — lets you learn the right dose in real time, adjusting as the data comes in, responding to what the patients’ bodies are actually telling you instead of clinging to what you assumed at the beginning.
I don’t use the word “marriage.” I don’t use the word “architecture.” I don’t draw any parallels that the audience could see, because this is science, not memoir, and the parallel exists only for me, in the private space where I know that learning to adapt in real time is also how I’m learning to build a life that doesn’t bend around someone else’s gravity.
The applause at the end is real. Not polite, not obligatory — real.
Three hundred people who came because the work matters, who listened because the data was compelling, who are clapping because Dr. Calla Merrifield stood at a podium for fifty minutes and proved that her mind is the most important thing about her.
Afterward, in the reception hall, I am introduced to people who know my work.
The department chair from Harvard, who tells me my framework is “elegant” and asks if I’d consider a visiting appointment.
The FDA biostatistics director, who wants to discuss how the adaptive model could be built into regulatory guidance documents.
A journal editor who asks if I’d write a review article for her flagship issue.
“Dr. Merrifield,” each of them says, and each time the name means me. Not him. Not the foundation. Not the family. Me.
The journal editor — Dr. Nolan, gray-haired, direct, the kind of woman who built her career by being smarter than every man in the room and quieter about it — sits down with me near the coffee station and says, “Your framework is going to change the FDA’s approach to dose-finding. You know that, right?”
“I’m hoping.”
“Don’t hope. Publish. The review article gives you the platform. You write the definitive piece, the one the regulators cite, and suddenly you’re not the researcher who developed the model — you’re the authority. That’s a different thing.”
I nod. She’s right. Authority and expertise are not the same — one is what you know, the other is what the world acknowledges you know. I have had expertise for years. What I haven’t had is authority that didn’t borrow from someone else’s name.
I am building it now. On my own foundation. With my own bricks.
Meanwhile, Langston’s world contracts.
I hear about it the way I hear about everything in the Boston biotech-philanthropy circuit — through Auden, who hears it through colleagues, who hear it through the quiet network of people who pay attention to where power goes when it shifts.
The news is not dramatic. There are no headlines, no press releases, no public statements.
There is just a slow, quiet change in the atmospheric pressure around the Merrifield name.
The foundation’s annual fundraiser, which usually draws three hundred donors and fills a ballroom, has been scaled back.
The official explanation is “strategic repositioning.” The unofficial explanation, relayed to Auden by a colleague who serves on the foundation’s advisory committee — the same committee I sat on — is that donors are asking questions.
About the fire. About the insurance. About the whispered story of a billionaire who left his wife in a burning house and is now trying to buy his way back.
“Nobody’s saying it out loud,” Auden tells me.
We’re at a café near campus, the kind with mismatched chairs and graduate students hunched over laptops.
“But the foundation’s major donors are — cautious.
They don’t want their names associated with a story that might become public.
It’s not that they think he’s guilty of anything.
It’s that they think the narrative is risky. ”
“The narrative.”
“Rich man leaves wife in fire. Wife is a respected academic. Wife files for divorce. Rich man sends flowers and donations and therapy notebooks. It’s — it has a shape, Cal. It has a shape that someone could write about, and the donors don’t want to be characters in that story.”
I drink my coffee. It’s better than the hospital coffee and worse than Langston’s espresso machine and exactly right for a Tuesday morning in a café where nobody knows my name except the barista, who spells it “Kala” on the cup.
I take the misspelling as a small kindness.
Today I am Kala. Kala with a grant and a plenary and a career that is hers.